Patents by Inventor Eve H. Barlow
Eve H. Barlow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190233510Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.Type: ApplicationFiled: August 6, 2018Publication date: August 1, 2019Inventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
-
Publication number: 20180362629Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and caninized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: ApplicationFiled: August 31, 2018Publication date: December 20, 2018Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Patent number: 10125192Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: GrantFiled: July 13, 2015Date of Patent: November 13, 2018Assignee: ZOETIS BELGIUM S.A.Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Patent number: 10093725Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: GrantFiled: July 14, 2015Date of Patent: October 9, 2018Assignee: ZOETIS BELGIUM S.A.Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Patent number: 10040852Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.Type: GrantFiled: January 6, 2016Date of Patent: August 7, 2018Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.Inventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
-
Patent number: 9505829Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: GrantFiled: August 19, 2011Date of Patent: November 29, 2016Assignee: ZOETIS BELGIUM S.A.Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20160264656Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: ApplicationFiled: July 14, 2015Publication date: September 15, 2016Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20160145334Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.Type: ApplicationFiled: January 6, 2016Publication date: May 26, 2016Inventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
-
Patent number: 9255146Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.Type: GrantFiled: August 29, 2013Date of Patent: February 9, 2016Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KGInventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
-
Publication number: 20160002324Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: ApplicationFiled: July 13, 2015Publication date: January 7, 2016Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20140199319Abstract: Disclosed herein are methods for improving the efficiency of the production of hybridomas, e.g., through enrichment of IgG expressing B cells. Also disclosed are hybridoma compositions produced using these methods as well as methods for producing antibodies with the hybridomas.Type: ApplicationFiled: December 13, 2013Publication date: July 17, 2014Applicant: AbbVie, Inc.Inventors: Jane SEAGAL, Eve H. BARLOW, Chung-Ming HSIEH, Jeffrey Yen PAN, Shawn M. JENNINGS, Mary R. LEDDY, Archana B. THAKUR
-
Publication number: 20140065155Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.Type: ApplicationFiled: August 29, 2013Publication date: March 6, 2014Inventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole Teusch
-
Publication number: 20130330348Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: ApplicationFiled: August 19, 2011Publication date: December 12, 2013Applicant: ABBOTT LABORATORIESInventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20110223176Abstract: Isolated binding proteins, e.g., antibodies, which bind to Basigin (BSG), e.g., human BSG2, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: March 8, 2011Publication date: September 15, 2011Applicant: ABBOTT LABORATORIESInventors: Eve H. Barlow, Chung-Ming Hsieh, Denise D. Karaoglu Hanzatian, Gillian Ann Kingsbury, Susan E. Morgan-Lappe, Edward B. Reilly, Fritz G. Buchanan, Yingchun Li
-
Patent number: 7906120Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.Type: GrantFiled: November 21, 2007Date of Patent: March 15, 2011Assignee: Abbott LaboratoriesInventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole E. Teusch
-
Publication number: 20080279859Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.Type: ApplicationFiled: November 21, 2007Publication date: November 13, 2008Applicant: ABBOTT LABORATORIESInventors: Mario Mezler, Achim Moeller, Reinhold Mueller, Bernhard K. Mueller, Tariq Ghayur, Eve H. Barlow, Martin Schmidt, Axel Meyer, Nicole E. Teusch
-
Patent number: 6589756Abstract: The invention provides improved immunoassay techniques for detecting the presence of analytes in a liquid sample. The present immunoassay methods utilize anti-allotypic monoclonal antibodies as capture reagents for primary binding proteins specific for the analytes of interest. The monoclonal antibodies are highly specific for the allotypic determinants present on the primary binding protein. The use of anti-allotypic monoclonal antibodies as capture reagents provides improved levels of specificity and accuracy of the immunoassay, in part because interference from endogenous immunoglobulins in the sample is significantly reduced. The invention further provides anti-allotypic monoclonal antibodies.Type: GrantFiled: September 15, 2000Date of Patent: July 8, 2003Assignee: Bayer CorporationInventor: Eve H. Barlow
-
Patent number: 6146836Abstract: The invention provides improved immunoassay techniques for detecting the presence of analytes in a liquid sample. The present immunoassay methods utilize anti-allotypic monoclonal antibodies as capture reagents for primary binding proteins specific for the analytes of interest. The monoclonal antibodies are highly specific for the allotypic determinants present on the primary binding protein. The use of anti-allotypic monoclonal antibodies as capture reagents provides improved levels of specificity and accuracy of the immunoassay, in part because interference from endogenous immunoglobulins in the sample is significantly reduced. The invention further provides anti-allotypic monoclonal antibodies.Type: GrantFiled: May 13, 1998Date of Patent: November 14, 2000Assignee: Bayer CorporationInventor: Eve H. Barlow
-
Patent number: 5783453Abstract: The assay described herein is predicated on an observation that when acridinium ester labeled tracers are bound to their corresponding binding conjugate immobilized on a metal oxide solid phase, the measurable chemiluminescent light emission of the labeled tracer bound to the solid phase is quenched as compared to the free fraction tracer that is unattached to the solid phase. According to the invention, a non-separation specific binding assay to detect or quantify the presence of an analyte is provided where the entire reaction mixture is flashed (including unreacted tracer) and modulated signal (because of the quench effect) is associated with a reference, thus determining the amount or presence of said analyte in said sample. Disadvantages inherent in heterogeneous assays employing multiple separations may be avoided using this non-separation method.Type: GrantFiled: June 29, 1995Date of Patent: July 21, 1998Assignee: Chiron Diagnostics CorporationInventors: Eve H. Barlow, Eddie Carroll, III, Joseph E. Connolly, Michael J. Lee, Richard A. Martinelli, John T. Unger